Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer

Br J Cancer. 2003 Sep 15;89(6):1031-4. doi: 10.1038/sj.bjc.6601195.

Abstract

Glomeruloid microvascular proliferation (GMP) in breast cancer independently adversely affected survival (relative risk 1.9, 95% CI: 1.2-3.0), particularly among women who received adjuvant chemotherapy (10-year survival 27 vs 69%, P=0.0003), and was significantly associated with p53 overexpression and BRCA1 germline mutations. The presence of GMP may influence treatment decisions.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Breast Neoplasms / blood supply*
  • Breast Neoplasms / metabolism*
  • Cell Division
  • Endothelium, Vascular / pathology
  • Female
  • Genes, BRCA1*
  • Genes, BRCA2
  • Germ-Line Mutation*
  • Humans
  • Immunoenzyme Techniques
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Staging
  • Neovascularization, Pathologic / pathology*
  • Prognosis
  • Survival Rate
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Tumor Suppressor Protein p53